文献速递免疫规划

系统分析氢氧化铝吸附TLR7激动剂(AS37)佐剂疫苗的人体反应揭示干扰素介导抗病毒反应的剂量依赖性和特异性激活

Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response.
PubMed 文献 · Vaccine · 2022-12-21

在一项I期研究(NCT02639351)中,健康成人随机接种单剂含铝佐剂的MenC-CRM197结合疫苗(对照)或AS37佐剂(TLR7a剂量12.5、25、50或100 μg)的MenC-CRM197结合疫苗;66名参与者同意进行全血转录组、细胞因子/趋化因子及髓系和淋巴系细胞反应分析。AS37佐剂组出现早期转录组反应,24 h达峰,随TLR7a剂量增加至50 μg而增强,一周内消退;CXCL10在24 h和3天升高,活化pDC和中间单核细胞在3天增加,Tfh细胞在7天增加并维持至28天,多数25、50、100 μg组受试者MenC特异性记忆B细胞较基线增加。TLR7a 25-50 μg可视为AS37的最佳剂量。

要点

  • AS37佐剂疫苗诱导早期转录组反应,24 h达峰,随TLR7a剂量增加至50 μg而增强。
  • AS37佐剂组CXCL10在24 h和3天升高,活化pDC和中间单核细胞在3天增加。
  • TLR7a 25-50 μg可视为AS37的最佳剂量。

核心结论

  • TLR7a吸附于铝佐剂可促进与TLR7结合一致的免疫特征,包括干扰素诱导基因、细胞因子及活化pDC、中间单核细胞、MenC特异性记忆B细胞和Tfh细胞频率的上调。
  • TLR7a 25-50 μg可视为AS37的最佳剂量,尤其对于佐剂MenC-CRM197结合疫苗。

研究设计与样本

  • I期研究(NCT02639351),健康成人随机接种单剂含铝佐剂的MenC-CRM197结合疫苗(对照)或AS37佐剂(TLR7a剂量12.5、25、50或100 μg)的MenC-CRM197结合疫苗。
  • 66名参与者同意进行全血转录组、全身细胞因子/趋化因子及多种髓系和淋巴系细胞反应分析作为探索性研究终点。
  • 血样采集于接种前、接种后6和24 h以及接种后3、7、28和180天。

主要发现

  • 全血基因表达谱显示早期AS37特异性转录组反应,24 h达峰,随TLR7a剂量增加至50 μg而增强,一般一周内消退。
  • 鉴定出5个差异表达基因簇,包括参与干扰素介导抗病毒反应的基因。
  • 30种细胞因子/趋化因子多重检测显示,AS37佐剂疫苗组接种后24 h和3天干扰素诱导趋化因子CXCL10(IP-10)水平升高。
  • AS37佐剂疫苗组接种后3天活化的浆细胞样树突状细胞(pDC)和中间单核细胞增加。
  • AS37佐剂疫苗组接种后7天Tfh细胞增加并维持至28天,多数接受25、50和100 μg TLR7a疫苗的受试者MenC特异性记忆B细胞反应较基线增加。

关键数值与推荐

  • TLR7a 25-50 μg可视为AS37的最佳剂量,尤其对于佐剂MenC-CRM197结合疫苗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The candidate Adjuvant System AS37 contains a synthetic toll-like receptor agonist (TLR7a) adsorbed to alum. In a phase I study (NCT02639351), healthy adults were randomised to receive one dose of licensed alum-adjuvanted meningococcal serogroup C (MenC-CRM197) conjugate vaccine (control) or MenC-CRM197 conjugate vaccine adjuvanted with AS37 (TLR7a dose 12.5, 25, 50 or 100 µg). A subset of 66 participants consented to characterisation of peripheral whole blood transcriptomic responses, systemic cytokine/chemokine responses and multiple myeloid and lymphoid cell responses as exploratory study endpoints. Blood samples were collected pre-vaccination, 6 and 24 h post-vaccination, and 3, 7, 28 and 180 days post-vaccination. The gene expression profile in whole blood showed an early, AS37-specific transcriptome response that peaked at 24 h, increased with TLR7a dose up to 50 µg and generally resolved within one week. Five clusters of differentially expressed genes were identified, including those involved in the interferon-mediated antiviral response. Evaluation of 30 cytokines/chemokines by multiplex assay showed an increased level of interferon-induced chemokine CXCL10 (IP-10) at 24 h and 3 days post-vaccination in the AS37-adjuvanted vaccine groups. Increases in activated plasmacytoid dendritic cells (pDC) and intermediate monocytes were detected 3 days post-vaccination in the AS37-adjuvanted vaccine groups. T follicular helper (Tfh) cells increased 7 days post-vaccination and were maintained at 28 days post-vaccination, particularly in the AS37-adjuvanted vaccine groups. Moreover, most of the subjects that received vaccine containing 25, 50 and 100 µg TLR7a showed an increased MenC-specific memory B cell responses versus baseline. These data show that the adsorption of TLR7a to alum promotes an immune signature consistent with TLR7 engagement, with up-regulation of interferon-inducible genes, cytokines and frequency of activated pDC, intermediate monocytes, MenC-specific memory B cells and Tfh cells. TLR7a 25-50 µg can be considered the optimal dose for AS37, particularly for the adjuvanted MenC-CRM197 conjugate vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Siena E, Schiavetti F, Borgogni E, et al. Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response. Vaccine. 2022. PMID: 36564274. doi:10.1016/j.vaccine.2022.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。